Literature DB >> 11836977

Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms?

Inmaculada Baeza Pertegaz, José Manuel Goikolea Alberdi, Eduard Parellada Rodón.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11836977      PMCID： PMC149796     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  7 in total

1.  Mental disorders from low-dose bromocriptine.

Authors:  K C Pearson
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

Review 2.  A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  J Webster
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

3.  Postpartum psychosis induced by bromocriptine and pseudoephedrine.

Authors:  R R Reeves; H B Pinkofsky
Journal:  J Fam Pract       Date:  1997-08       Impact factor: 0.493

4.  Bromocriptine and psychosis: a literature review.

Authors:  A Boyd
Journal:  Psychiatr Q       Date:  1995

5.  Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.

Authors:  A E Pontiroli; L Cammelli; P Baroldi; G Pozza
Journal:  J Clin Endocrinol Metab       Date:  1987-11       Impact factor: 5.958

Review 6.  Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  C P Rains; H M Bryson; A Fitton
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

7.  Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies.

Authors:  M Morissette; M Goulet; R Grondin; P Blanchet; P J Bédard; T Di Paolo; D Lévesque
Journal:  Eur J Neurosci       Date:  1998-08       Impact factor: 3.386
  7 in total
  1 in total

1.  Beneficial effect of pramipexole for motor function and depression in Parkinson's disease.

Authors:  Osamu Kano; Ken Ikeda; Tetsuhito Kiyozuka; Konosuke Iwamoto; Hirono Ito; Yuji Kawase; Ryuta Sato; Toshiki Fujioka; Yo Araki; Shigeji Baba; Yasuo Iwasaki
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.